| Membrane transporters in drug development KM Giacomini, SM Huang, DJ Tweedie, LZ Benet, KLR Brouwer, X Chu, ... Nature Reviews Drug Discovery 9 (3), 215-236, 2010 | 3536* | 2010 |
| Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites MJ Zamek-Gliszczynski, KA Hoffmaster, K Nezasa, MN Tallman, ... European journal of pharmaceutical sciences 27 (5), 447-486, 2006 | 310 | 2006 |
| Why Clinical Inhibition of Efflux Transport at the Blood-Brain Barrier is Unlikely: The ITC Evidence-Based Position JC Kalvass, JW Polli, DL Bourdet, B Feng, SM Huang, X Liu, QR Smith, ... Clinical Pharmacology & Therapeutics, 2013 | 221 | 2013 |
| ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport‐mediated PK and DDIs in humans MJ Zamek‐Gliszczynski, CA Lee, A Poirier, J Bentz, X Chu, H Ellens, ... Clinical Pharmacology & Therapeutics 94 (1), 64-79, 2013 | 220 | 2013 |
| Transporters in drug development: 2018 ITC recommendations for transporters of emerging clinical importance MJ Zamek‐Gliszczynski, ME Taub, PP Chothe, X Chu, KM Giacomini, ... Clinical Pharmacology & Therapeutics 104 (5), 890-899, 2018 | 219 | 2018 |
| Pharmacokinetics of 5 (and 6)-carboxy-2′, 7′-dichlorofluorescein and its diacetate promoiety in the liver MJ Zamek-Gliszczynski, H Xiong, NJ Patel, RZ Turncliff, GM Pollack, ... Journal of Pharmacology and Experimental Therapeutics 304 (2), 801-809, 2003 | 192 | 2003 |
| Clinical probes and endogenous biomarkers as substrates for transporter drug‐drug interaction evaluation: perspectives from the international transporter consortium X Chu, M Liao, H Shen, K Yoshida, AA Zur, V Arya, A Galetin, ... Clinical Pharmacology & Therapeutics 104 (5), 836-864, 2018 | 163 | 2018 |
| Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction … CA Lee, MA O’Connor, TK Ritchie, A Galetin, JA Cook, ... Drug Metabolism and Disposition 43 (4), 490-509, 2015 | 147 | 2015 |
| Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models SB Peng, X Zhang, D Paul, LM Kays, W Gough, J Stewart, MT Uhlik, ... Molecular cancer therapeutics 14 (2), 480-490, 2015 | 138 | 2015 |
| Evaluation of the role of multidrug resistance-associated protein (Mrp) 3 and Mrp4 in hepatic basolateral excretion of sulfate and glucuronide metabolites of acetaminophen, 4 … MJ Zamek-Gliszczynski, K Nezasa, X Tian, AS Bridges, K Lee, ... Journal of Pharmacology and Experimental Therapeutics 319 (3), 1485-1491, 2006 | 136 | 2006 |
| The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice MJ Zamek-Gliszczynski, K Nezasa, X Tian, JC Kalvass, NJ Patel, TJ Raub, ... Molecular pharmacology 70 (6), 2127-2133, 2006 | 121 | 2006 |
| The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects IH Song, J Zong, J Borland, F Jerva, B Wynne, MJ Zamek-Gliszczynski, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 72 (4), 400-407, 2016 | 112 | 2016 |
| Ablation of both organic cation transporter (OCT) 1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics JW Higgins, DW Bedwell, MJ Zamek-Gliszczynski Drug metabolism and disposition 40 (6), 1170-1177, 2012 | 112 | 2012 |
| Importance of hepatic transporters in clinical disposition of drugs and their metabolites M Patel, KS Taskar, MJ Zamek‐Gliszczynski The Journal of Clinical Pharmacology 56, S23-S39, 2016 | 111 | 2016 |
| Highlights from the International Transporter Consortium Second Workshop MJ Zamek-Gliszczynski, KA Hoffmaster, DJ Tweedie, KM Giacomini, ... Clinical Pharmacology & Therapeutics 92 (5), 553-556, 2012 | 108 | 2012 |
| Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 Knockout Rats Using Loperamide, Paclitaxel, Sulfasalazine, and Carboxydichlorofluorescein Pharmacokinetics MJ Zamek-Gliszczynski, DW Bedwell, JQ Bao, JW Higgins Drug Metabolism and Disposition 40 (9), 1825-1833, 2012 | 103 | 2012 |
| A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer S Pant, SF Jones, CD Kurkjian, JR Infante, KN Moore, HA Burris, ... European journal of cancer 56, 1-9, 2016 | 99 | 2016 |
| Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin … JW Higgins, JQ Bao, AB Ke, JR Manro, JK Fallon, PC Smith, ... Drug Metabolism and Disposition 42 (1), 182-192, 2014 | 96 | 2014 |
| Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat MJ Zamek-Gliszczynski, KA Hoffmaster, JE Humphreys, X Tian, K Nezasa, ... Journal of Pharmacology and Experimental Therapeutics 319 (1), 459-467, 2006 | 94 | 2006 |
| Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1 MJ Zamek-Gliszczynski, KA Hoffmaster, X Tian, R Zhao, JW Polli, ... Drug metabolism and disposition 33 (8), 1158-1165, 2005 | 92 | 2005 |
